Excessive bleeding from a common skin abnormality was the first indication of von Willebrand disease (VWD) in a 1-year-old girl, highlighting the importance of…
News
The preventive treatment Adzynma (recombinant human ADAMTS13) is safe and effective at reducing disease relapses for people with congenital thrombotic thrombocytopenic purpura (TTP), and…
Combining low-dose eltrombopag with reduced-dose prednisone may be an effective approach for controlling immune thrombocytopenia (ITP) while minimizing the risk of medication side effects,…
Although more people with von Willebrand disease (VWD) have given birth over the past two decades, the rates of certain complications, such as prebirth…
A combination of blood biomarkers can help predict the short-term risk of death for people admitted to the hospital with thrombotic thrombocytopenic purpura (TTP),…
People with immune thrombocytopenia (ITP) who have had their spleens surgically removed may face an increased risk of clotting problems from ITP treatments…
Adding Cyklokapron (tranexamic acid) to Vonvendi (recombinant von Willebrand factor) does not appear to reduce blood loss following childbirth for women with von Willebrand…
Levels of anti-ADAMTS13 antibodies measured after therapeutic plasma exchange (TPE) are associated with the time it takes to achieve normalization of ADAMTS13 activity in people…
Casi Pharmaceuticals has been given the all-clear to start dosing a fifth group of patients in a clinical trial testing its treatment candidate CID-103…
The U.S. Food and Drug Administration (FDA) has expanded its approval of Vonvendi (recombinant von Willebrand factor), a treatment for von Willebrand disease (VWD).
